Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine

Detalhes bibliográficos
Autor(a) principal: Silva,Alessandra D.
Data de Publicação: 2009
Outros Autores: Esteves,Paulo A., Dezen,Diogenes, Oliveira,Anna P., Spilki,Fernando R., Campos,Fabrício S., Franco,Ana C., Roehe,Paulo M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Pesquisa Veterinária Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-736X2009000700008
Resumo: Bovine herpesvirus type 1 (BoHV-1) is recognized as a major cause of economic losses in cattle. Vaccination has been widely applied to minimize losses induced by BoHV-1 infections. We have previously reported the development of a differential BoHV-1 vaccine, based on a recombinant glycoprotein E (gE)-deleted virus (265gE-). In present paper the efficacy of such recombinant was evaluated as an inactivated vaccine. Five BoHV-1 seronegative calves were vaccinated intramuscularly on day 0 and boostered 30 days later with an inactivated, oil adjuvanted vaccine containing an antigenic mass equivalent to 10(7.0) fifty per cent cell culture infectious doses (CCID50) of 265gE-. Three calves were kept as non vaccinated controls. On day 60 post vaccination both vaccinated and controls were challenged with the virulent parental strain. No clinical signs or adverse effects were seen after or during vaccination. After challenge, 2/5 vaccinated calves showed mild clinical signs of infection, whereas all non vaccinated controls displayed intense rhinotracheitis and shed virus for longer and to higher titres than vaccinated calves. Serological responses were detected in all vaccinated animals after the second dose of vaccine, but not on control calves. Following corticosteroid administration in attempting to induce reactivation of the latent infection, no clinical signs were observed in vaccinated calves, whereas non vaccinated controls showed clinical signs of respiratory disease. In view of its immunogenicity and protective effect upon challenge with a virulent BoHV-1, the oil adjuvanted preparation with the inactivated 265gE- recombinant was shown to be suitable for use as a vaccine.
id EMBRAPA-2_065a9aec9bc69a0b2bb5e709c2f7c992
oai_identifier_str oai:scielo:S0100-736X2009000700008
network_acronym_str EMBRAPA-2
network_name_str Pesquisa Veterinária Brasileira (Online)
repository_id_str
spelling Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccineBovine herpesvirus type 1BoHV-1recombinant vaccineinactivated vaccineBovine herpesvirus type 1 (BoHV-1) is recognized as a major cause of economic losses in cattle. Vaccination has been widely applied to minimize losses induced by BoHV-1 infections. We have previously reported the development of a differential BoHV-1 vaccine, based on a recombinant glycoprotein E (gE)-deleted virus (265gE-). In present paper the efficacy of such recombinant was evaluated as an inactivated vaccine. Five BoHV-1 seronegative calves were vaccinated intramuscularly on day 0 and boostered 30 days later with an inactivated, oil adjuvanted vaccine containing an antigenic mass equivalent to 10(7.0) fifty per cent cell culture infectious doses (CCID50) of 265gE-. Three calves were kept as non vaccinated controls. On day 60 post vaccination both vaccinated and controls were challenged with the virulent parental strain. No clinical signs or adverse effects were seen after or during vaccination. After challenge, 2/5 vaccinated calves showed mild clinical signs of infection, whereas all non vaccinated controls displayed intense rhinotracheitis and shed virus for longer and to higher titres than vaccinated calves. Serological responses were detected in all vaccinated animals after the second dose of vaccine, but not on control calves. Following corticosteroid administration in attempting to induce reactivation of the latent infection, no clinical signs were observed in vaccinated calves, whereas non vaccinated controls showed clinical signs of respiratory disease. In view of its immunogenicity and protective effect upon challenge with a virulent BoHV-1, the oil adjuvanted preparation with the inactivated 265gE- recombinant was shown to be suitable for use as a vaccine.Colégio Brasileiro de Patologia Animal - CBPA2009-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-736X2009000700008Pesquisa Veterinária Brasileira v.29 n.7 2009reponame:Pesquisa Veterinária Brasileira (Online)instname:Colégio Brasileiro de Patologia Animal (CBPA)instacron:EMBRAPA10.1590/S0100-736X2009000700008info:eu-repo/semantics/openAccessSilva,Alessandra D.Esteves,Paulo A.Dezen,DiogenesOliveira,Anna P.Spilki,Fernando R.Campos,Fabrício S.Franco,Ana C.Roehe,Paulo M.eng2009-09-21T00:00:00Zoai:scielo:S0100-736X2009000700008Revistahttp://www.pvb.com.br/https://old.scielo.br/oai/scielo-oai.phpcolegio@cbpa.org.br||pvb@pvb.com.br0100-736X1678-5150opendoar:2009-09-21T00:00Pesquisa Veterinária Brasileira (Online) - Colégio Brasileiro de Patologia Animal (CBPA)false
dc.title.none.fl_str_mv Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine
title Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine
spellingShingle Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine
Silva,Alessandra D.
Bovine herpesvirus type 1
BoHV-1
recombinant vaccine
inactivated vaccine
title_short Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine
title_full Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine
title_fullStr Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine
title_full_unstemmed Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine
title_sort Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine
author Silva,Alessandra D.
author_facet Silva,Alessandra D.
Esteves,Paulo A.
Dezen,Diogenes
Oliveira,Anna P.
Spilki,Fernando R.
Campos,Fabrício S.
Franco,Ana C.
Roehe,Paulo M.
author_role author
author2 Esteves,Paulo A.
Dezen,Diogenes
Oliveira,Anna P.
Spilki,Fernando R.
Campos,Fabrício S.
Franco,Ana C.
Roehe,Paulo M.
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva,Alessandra D.
Esteves,Paulo A.
Dezen,Diogenes
Oliveira,Anna P.
Spilki,Fernando R.
Campos,Fabrício S.
Franco,Ana C.
Roehe,Paulo M.
dc.subject.por.fl_str_mv Bovine herpesvirus type 1
BoHV-1
recombinant vaccine
inactivated vaccine
topic Bovine herpesvirus type 1
BoHV-1
recombinant vaccine
inactivated vaccine
description Bovine herpesvirus type 1 (BoHV-1) is recognized as a major cause of economic losses in cattle. Vaccination has been widely applied to minimize losses induced by BoHV-1 infections. We have previously reported the development of a differential BoHV-1 vaccine, based on a recombinant glycoprotein E (gE)-deleted virus (265gE-). In present paper the efficacy of such recombinant was evaluated as an inactivated vaccine. Five BoHV-1 seronegative calves were vaccinated intramuscularly on day 0 and boostered 30 days later with an inactivated, oil adjuvanted vaccine containing an antigenic mass equivalent to 10(7.0) fifty per cent cell culture infectious doses (CCID50) of 265gE-. Three calves were kept as non vaccinated controls. On day 60 post vaccination both vaccinated and controls were challenged with the virulent parental strain. No clinical signs or adverse effects were seen after or during vaccination. After challenge, 2/5 vaccinated calves showed mild clinical signs of infection, whereas all non vaccinated controls displayed intense rhinotracheitis and shed virus for longer and to higher titres than vaccinated calves. Serological responses were detected in all vaccinated animals after the second dose of vaccine, but not on control calves. Following corticosteroid administration in attempting to induce reactivation of the latent infection, no clinical signs were observed in vaccinated calves, whereas non vaccinated controls showed clinical signs of respiratory disease. In view of its immunogenicity and protective effect upon challenge with a virulent BoHV-1, the oil adjuvanted preparation with the inactivated 265gE- recombinant was shown to be suitable for use as a vaccine.
publishDate 2009
dc.date.none.fl_str_mv 2009-07-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-736X2009000700008
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-736X2009000700008
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0100-736X2009000700008
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Colégio Brasileiro de Patologia Animal - CBPA
publisher.none.fl_str_mv Colégio Brasileiro de Patologia Animal - CBPA
dc.source.none.fl_str_mv Pesquisa Veterinária Brasileira v.29 n.7 2009
reponame:Pesquisa Veterinária Brasileira (Online)
instname:Colégio Brasileiro de Patologia Animal (CBPA)
instacron:EMBRAPA
instname_str Colégio Brasileiro de Patologia Animal (CBPA)
instacron_str EMBRAPA
institution EMBRAPA
reponame_str Pesquisa Veterinária Brasileira (Online)
collection Pesquisa Veterinária Brasileira (Online)
repository.name.fl_str_mv Pesquisa Veterinária Brasileira (Online) - Colégio Brasileiro de Patologia Animal (CBPA)
repository.mail.fl_str_mv colegio@cbpa.org.br||pvb@pvb.com.br
_version_ 1754122229574008832